This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Macular Disorders  • Ocular/ Adnexal Tumors  • Retinal/ Chorioretinal Disorders  • Immunology  • Immunology, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

Lee M. Jampol, MD; Gerald A. Fishman, MD

Arch Ophthalmol. 2009;127(4):573-575.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

In this month's issue of Archives, Ferreyra and coworkers¹ report their experience treating patients who have autoimmune retinopathy (AIR) with immunosuppression. Included among the 30 patients in their retrospective study were 6 patients with cancer-associated retinopathy, 13 with nonparaneoplastic AIR, and 11 with nonparaneoplastic AIR with cystoid macular edema.

Outcome measures that the authors used included an improvement in Snellen visual acuity by 2 or more lines, expansion of the visual field by more than 25%, resolution of cystoid macular edema, and improvement in electroretinogram (ERG) amplitudes. The authors cited an improvement in 21 of their 30 patients (70%): 100% of patients with cancer-associated retinopathy, 54% of patients with nonparaneoplastic AIR, and 73% of patients with nonparaneoplastic AIR with cystoid macular edema. Five of the 21 patients (24%) showed improvement in visual acuity; 15 of 21 (71%) improved their visual field . . . [Full Text of this Article]

AUTHOR INFORMATION


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

Management of Autoimmune Retinopathies With Immunosuppression
Henry A. Ferreyra, Thiran Jayasundera, Naheed W. Khan, Shirley He, Ying Lu, and John R. Heckenlively
Arch Ophthalmol. 2009;127(4):390-397.
ABSTRACT | FULL TEXT